Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

David Cunningham, Daniel Virgil Thomas Catenacci, Ірина Давиденко et al.|Journal of Clinical Oncology|2015

Cited by 144